Search
Wednesday, 21 Jan 2026
10:30am New Delhi | 1:00pm Singapore | 2:00pm Seoul/Tokyo | 4:00pm Sydney
Peptide-based biomarkers and biotherapeutic agents such as GLP-1 present significant challenges to meet quantitative sensitivity requirements. Peptide-based markers tend to be at low dosing/circulating levels in plasma and when analyzed using LC-MSn, ionize into multiple precursor charge states diluting the overall signal used for targeted quantitation.
To meet the experimental requirements for GLP-1 quantitation, the Thermo ScientificTM StellarTM MS was incorporated into a Thermo Scientific workflow demonstrating extended quantitative sensitivity in plasma matrices. Stellar MS leveraged parallel reaction monitoring (PRM acquisition using MS2 and MS3 acquisition methods depending on sample preparation performed up front. Acquiring data using PRM enabled co-addition of multiple MS2 or MS3 product ions improving S/N measurements at spiking levels below 0.5 ng/mL.
In addition to the LC-MSn analysis, a detailed description of Chromeleon CDS software will be presented on managing the entire experiment, from method optimization to report generation. Key elements will be shown on managing different scan events acquired on Stellar MS for downstream data processing and reporting. Finally, demonstrations of CBMX operation will be shown for study transfer or storage.
Who should attend:
- Lab scientists and technicians working on quantitative analysis
- Pharmaceutical and Biotechnology Professionals
- Clinical Researchers and Biomarker Verification Experts
Speakers
Dr. Hao Yang
Senior Application Scientist
Thermo Fisher Scientific
Dr. Hao Yang is a senior application scientist in the Omics application group within Chromatography and Mass Spectrometry division. He has been with Thermo Fisher Scientific for 6 years primarily focusing on developing analytical methodologies to support Pharma and Biopharmaceutical customers. Currently, he is focusing on developing new methods to characterize antibody oligo conjugates, as well as bioanalysis of therapeutic oligos and peptides.
Dr. Richard Law
Product Manager
Thermo Fisher Scientific
With a background in analytical chemistry and mass spectrometry, Richard is the Product Manager for targeted MS using Chromeleon CDS. He has extensive experience developing applications using LC and GC–MS technologies, especially GC-triple quadrupole MS/MS and HRAM, and has worked across several industry segments.
Live Q&A Speaker
Dr. Hao Yang
Senior Application Scientist
Thermo Fisher Scientific
Scott Peterman
Sr. Global Marketing Manager
Thermo Fisher Scientific
Scott received his Ph. D. from Texas A&M University in 2001 and began working with Thermo Fisher Scientific as an application chemist, transitioned to Proteomics Marketing to initiate the Targeted Peptide Quantitation Program with triple quadrupole mass spectrometers, and joined the BRIMS Center in 2010 focusing on routine workflows for clinical/translational research. Scott transitioned into the Sr. Global Marketing Manager for Tribrid mass spectrometers and associated products in 2018 and focuses on applications for small, large, and larger molecules.